EQ
Equillium, Inc.
Biotechnology
Market Cap$271M
5Y Perf.-4.7%
Build Your Comparison
Side-by-side financial analysisEQ
RAPT
Try popular comparisons:
Stock Comparison
EQ vs RAPT
Revenue, margins, valuation, and 5-year total return — side by side.
RAPT
RAPT Therapeutics, Inc.
Biotechnology
Market Cap$296M
5Y Perf.-75.0%
EQ vs RAPT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  EQ |  RAPT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $271M | $296M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-19M | $-106M |
| Total Debt | $719K | $4M |
| Cash & Equiv. | $30M | $170M |
EQ vs RAPT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EQ
RAPT
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Equillium, Inc. (EQ) | 100 | 95.3 | -4.7% |
| RAPT Therapeutics, … (RAPT) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EQ vs RAPT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EQ leads in 3 of 5 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. RAPT Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
🥇EQ emerged as the overall leader. Track its performance:
EQ
Equillium, Inc.
The Income Pick
EQ carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.50
- Lower volatility, beta 0.50, Low D/E 2.5%, current ratio 10.32x
- Beta 0.50, current ratio 10.32x
Best for: income & stability and sleep-well-at-night
RAPT
RAPT Therapeutics, Inc.
The Growth Play
RAPT is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -4.6%
- -44.2% 10Y total return vs EQ's -79.9%
- 1.5% revenue growth vs EQ's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  RAPT | 1.5% revenue growth vs EQ's -100.0% |
| Stability / Safety |  EQ | Beta 0.50 vs RAPT's 0.63 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | EQ | +6.3% vs RAPT's +5.6% |
| Efficiency (ROA) | EQ | -53.7% ROA vs RAPT's -54.7%, ROIC -88.8% vs -155.7% |
EQ vs RAPT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRAPTLAGGINGEQ
EQEquillium, Inc.
1leads
RAPTRAPT Therapeutics, In…
2leads
6 Total Categories
CATEGORYLEADERvs EQMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RAPT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RAPT5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
EQ5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RAPT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
EQ and RAPT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | EQEquillium, Inc. | RAPTRAPT Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$20M | -$112M |
| Net IncomeAfter-tax profit | -$19M | -$106M |
| Free Cash FlowCash after capex | -$19M | -$87M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +77.0% | +82.9% |
RAPT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — EQ and RAPT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | EQEquillium, Inc. | RAPTRAPT Therapeutics… |
|---|---|---|
| Market CapShares × price | $271M | $296M |
| Enterprise ValueMkt cap + debt − cash | $241M | $130M |
| Trailing P/EPrice ÷ TTM EPS | -7.21x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 9.03x | 1.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — EQ and RAPT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RAPT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
EQ delivers a -61.4% return on equity — every $100 of shareholder capital generates $-61 in annual profit, vs $-62 for RAPT. RAPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to EQ's 0.03x. On the Piotroski fundamental quality scale (0–9), RAPT scores 2/9 vs EQ's 1/9, reflecting mixed financial health.
| Metric | EQEquillium, Inc. | RAPTRAPT Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -61.4% | -61.8% |
| ROA (TTM)Return on assets | -53.7% | -54.7% |
| ROICReturn on invested capital | -88.8% | -155.7% |
| ROCEReturn on capital employed | -98.1% | -79.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.03x | 0.02x |
| Net DebtTotal debt minus cash | -$30M | -$165M |
| Cash & Equiv.Liquid assets | $30M | $170M |
| Total DebtShort + long-term debt | $719,000 | $4M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
RAPT leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
EQ leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EQ five years ago would be worth $4,584 today (with dividends reinvested), compared to $3,904 for RAPT. Over the past 12 months, EQ leads with a +628.0% total return vs RAPT's +559.1%. The 3-year compound annual growth rate (CAGR) favors EQ at 58.2% vs RAPT's -29.4% — a key indicator of consistent wealth creation.
| Metric | EQEquillium, Inc. | RAPTRAPT Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | +83.7% | +82.1% |
| 1-Year ReturnPast 12 months | +628.0% | +559.1% |
| 3-Year ReturnCumulative with dividends | +295.8% | -64.8% |
| 5-Year ReturnCumulative with dividends | -54.2% | -61.0% |
| 10-Year ReturnCumulative with dividends | -79.9% | -44.2% |
| CAGR (3Y)Annualised 3-year return | +58.2% | -29.4% |
EQ leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — EQ and RAPT each lead in 1 of 2 comparable metrics.
Risk & Volatility
EQ is the less volatile stock with a 0.50 beta — it tends to amplify market swings less than RAPT's 0.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPT currently trades 100.0% from its 52-week high vs EQ's 81.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EQEquillium, Inc. | RAPTRAPT Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.50x | 0.63x |
| 52-Week HighHighest price in past year | $3.43 | $58.02 |
| 52-Week LowLowest price in past year | $0.27 | $6.88 |
| % of 52W HighCurrent price vs 52-week peak | +81.9% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 78.9 |
| Avg Volume (50D)Average daily shares traded | 559K | 10.8M |
Evenly matched — EQ and RAPT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EQ as "Buy" and RAPT as "Hold". Consensus price targets imply 122.4% upside for EQ (target: $6) vs -0.0% for RAPT (target: $58).
| Metric | EQEquillium, Inc. | RAPTRAPT Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $6.25 | $58.00 |
| # AnalystsCovering analysts | 12 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RAPT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EQ leads in 1 (Total Returns). 2 tied.
Best OverallRAPT Therapeutics, Inc. (RAPT)Leads 2 of 6 categories
Loading custom metrics...
EQ vs RAPT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EQ or RAPT a better buy right now?
Analysts rate Equillium, Inc.
(EQ) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EQ or RAPT?
Over the past 5 years, Equillium, Inc.
(EQ) delivered a total return of -54. 2%, compared to -61. 0% for RAPT Therapeutics, Inc. (RAPT). Over 10 years, the gap is even starker: RAPT returned -44. 2% versus EQ's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EQ or RAPT?
By beta (market sensitivity over 5 years), Equillium, Inc.
(EQ) is the lower-risk stock at 0. 50β versus RAPT Therapeutics, Inc. 's 0. 63β — meaning RAPT is approximately 25% more volatile than EQ relative to the S&P 500. On balance sheet safety, RAPT Therapeutics, Inc. (RAPT) carries a lower debt/equity ratio of 2% versus 3% for Equillium, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — EQ or RAPT?
On earnings-per-share growth, the picture is similar: RAPT Therapeutics, Inc.
grew EPS -4. 6% year-over-year, compared to -69. 6% for Equillium, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EQ or RAPT?
Equillium, Inc.
(EQ) is the more profitable company, earning 0. 0% net margin versus 0. 0% for RAPT Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EQ leads at 0. 0% versus 0. 0% for RAPT. At the gross margin level — before operating expenses — EQ leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — EQ or RAPT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is EQ or RAPT better for a retirement portfolio?
For long-horizon retirement investors, Equillium, Inc.
(EQ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 50)). Both have compounded well over 10 years (EQ: -79. 9%, RAPT: -44. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EQ and RAPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.